Jeffrey Nau
Director/Board Member chez BioNJ, Inc.
Profil
Jeffrey A.
Nau is currently the Treasurer & Director at BioNJ, Inc. and the Director at Ophthalmology Foundation.
Previously, he served as the President & Chief Executive Officer at Oyster Point Pharma, Inc. from 2017 to 2023.
He was also the Director-Medical Sciences at Genentech, Inc. from 2011 to 2013 and the Vice President-Medical & Clinical Affairs at NeoVista, Inc. from 2006 to 2011.
Additionally, he held positions as the Vice President-Clinical & Medical Affairs at IVERIC bio, Inc. from 2013 to 2017 and as the President-Eye Care Division at Viatris, Inc. He has also worked as a Clinical Program Manager at Genaera Pharmaceuticals and as a Research Fellow at Wills Eye Health System & Wills Eye Institute.
Dr. Nau holds a doctorate degree from Walden University LLC, an undergraduate degree from Stony Brook University, and a graduate degree from Drexel University College of Medicine.
Postes actifs de Jeffrey Nau
| Sociétés | Poste | Début |
|---|---|---|
BioNJ, Inc.
 BioNJ, Inc. Miscellaneous Commercial ServicesCommercial Services BioNJ, Inc. is based in Trenton, NJ. BioNJ, Inc. is a life sciences trade association with nearly 400 member companies. The company supports the discovery, development, and commercialization of therapies and cures that save and improve lives. BioNJ drives capital formation, fosters entrepreneurship, advocates for medical innovation, provides access to talent and education, and offers critical commercial resources. The company also serves as a clearinghouse for funding information and opportunities. The company was founded in 1994 by James J. Marino, Jayne C. Gershkowitz, Abraham Abuchowski. The CEO is Debbie Hart. | Director/Board Member | 13/02/2020 |
| Ophthalmology Foundation | Director/Board Member | 29/06/2023 |
Anciens postes connus de Jeffrey Nau
| Sociétés | Poste | Fin |
|---|---|---|
| VIATRIS INC. | Corporate Officer/Principal | 01/01/2024 |
| OYSR POIN | Chief Executive Officer | 01/01/2023 |
| IVERIC BIO, INC. | Chief Tech/Sci/R&D Officer | 01/03/2017 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Chief Tech/Sci/R&D Officer | 01/07/2013 |
NeoVista, Inc.
 NeoVista, Inc. Medical SpecialtiesHealth Technology NeoVista, Inc. develops device-based therapy for age-related macular degeneration (AMD). The firm's technology utilizes targeted strontium 90 beta radiation in a one-time surgical procedure and this technology has the possibility to reduce the burden that wet AMD places on healthcare providers, patients, and the healthcare system. The company was founded in 2002 and is headquartered in Newark, CA. | Chief Tech/Sci/R&D Officer | 01/10/2011 |
Formation de Jeffrey Nau
| Walden University LLC | Doctorate Degree |
| Stony Brook University | Undergraduate Degree |
| Drexel University College of Medicine | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| VIATRIS INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
NeoVista, Inc.
NeoVista, Inc. Medical SpecialtiesHealth Technology NeoVista, Inc. develops device-based therapy for age-related macular degeneration (AMD). The firm's technology utilizes targeted strontium 90 beta radiation in a one-time surgical procedure and this technology has the possibility to reduce the burden that wet AMD places on healthcare providers, patients, and the healthcare system. The company was founded in 2002 and is headquartered in Newark, CA. | Health Technology |
| Genaera Pharmaceuticals | |
Wills Eye Health System & Wills Eye Institute
 Wills Eye Health System & Wills Eye Institute Medical/Nursing ServicesHealth Services Wills Eye Health System & Wills Eye Institute is a renowned ophthalmology hospital established in 1832 as the first hospital in the United States specializing in eye care. The hospital is located in Philadelphia, PA. Wills Eye is consistently ranked as one of America's top ophthalmology hospitals by U.S. News & World Report and has the most nationally ranked ophthalmologists in the country. It is also the #1 academic training for its residency program as voted by physicians in the nation. Wills Eye provides a full range of primary and subspecialty eye care services, including cataract, cornea, retina, emergency care, glaucoma, neuro-ophthalmology, ocular oncology, oculoplastics, pathology, pediatric ophthalmology and ocular genetics, and refractive surgery. The hospital also has a network of seven multi-specialty, ambulatory surgery centers throughout the tristate area. | Health Services |
IVERIC bio, Inc.
 IVERIC bio, Inc. Pharmaceuticals: GenericHealth Technology IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ. | Health Technology |
BioNJ, Inc.
BioNJ, Inc. Miscellaneous Commercial ServicesCommercial Services BioNJ, Inc. is based in Trenton, NJ. BioNJ, Inc. is a life sciences trade association with nearly 400 member companies. The company supports the discovery, development, and commercialization of therapies and cures that save and improve lives. BioNJ drives capital formation, fosters entrepreneurship, advocates for medical innovation, provides access to talent and education, and offers critical commercial resources. The company also serves as a clearinghouse for funding information and opportunities. The company was founded in 1994 by James J. Marino, Jayne C. Gershkowitz, Abraham Abuchowski. The CEO is Debbie Hart. | Commercial Services |
Oyster Point Pharma, Inc.
 Oyster Point Pharma, Inc. Pharmaceuticals: MajorHealth Technology Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its product candidate, OC-01, is a nicotinic acetylcholine receptor agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. The company was founded by Michael and is Ackermann in June 30, 2015 headquartered in Princeton, NJ. | Health Technology |
| Ophthalmology Foundation |
